Sign in / Join Now
ETFs & Funds
Any ideas what's hammering $
Probably the study drug assignment errors in the BENEFIT-ALS trial that they mentioned in their Q2 results yesterday evening...
That was old news a week or two ago.
Canaccord Genuity Conference Transcript @
Add a reply...
Latest StockTalks »
people get CYTK breaking news and analysis by email alert.
Get email alerts on CYTK »
Get latest price
From other sites
Cytokinetics Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv
at TheStreet (Tue, 7:30AM)
Cytokinetics To Announce Third Quarter Results On October 27, 2016
at TheStreet (Oct 13, 2016)
Commit To Buy Cytokinetics At $7, Earn 12.4% Annualized Using Options
at TheStreet (Sep 30, 2016)
Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas
at TheStreet (Sep 29, 2016)
Short Interest Drops 28.6% For CYTK
at TheStreet (Sep 27, 2016)